AMGEN INC

Amgen Inc.: A stable biotech stock with rising earnings, a 4.1% dividend, and a diversified pipeline—ideal for income‑focused investors seeking long‑term growth.

Amgen’s July cyber breach raises regulatory scrutiny, potential PHI exposure, and investor risk—yet its oncology and cardiovascular pipeline remains strong.

Explore how Sarepta’s new CEO and gene‑therapy strategies illuminate biotech market‑access, patent cliffs, and M&A trends for sustainable growth.

Amgen’s steady dividends and strong cash flow keep it a key driver in Schwab’s SCHD ETF, yet patent cliffs and biosimilar pressure could erode long‑term returns.

Amgen faces FDA and EMA withdrawal of Tavneos after NEJM retraction, with data integrity and liver‑injury concerns highlighted.

FDA questions Amgen’s Tavneos data integrity for rare liver disease. Discover how regulatory scrutiny, post‑approval evidence, and market impact shape this therapy’s future.

Amgen hires an independent review to counter the FDA’s Tavneos withdrawal proposal, aiming to prove efficacy and safety amid rising hepatotoxicity concerns.

Amgen’s VESALIUS‑CV trial shows Evolocumab cuts major heart events by 34% in high‑risk diabetics, while real‑world GLP‑1 data reveal adherence gaps that need new strategies.

Amgen’s ADA 86th presentation reveals Repatha® cuts CV events by 23% in high‑risk diabetics and shows real‑world GLP‑1 persistence improves HbA1c and weight, highlighting new obesity‑centric therapies.

Amgen’s rising stock shows biotech resilience amid market swings, powered by proven drugs like Repatha® and a pipeline of oncology, nephrology and inflammation therapies that promise sustained growth.